98,467 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by First National Bank of Omaha

First National Bank of Omaha purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 98,467 shares of the medical equipment provider’s stock, valued at approximately $8,919,000.

Several other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after purchasing an additional 192,517 shares during the last quarter. Dodge & Cox lifted its holdings in shares of Zimmer Biomet by 5.1% in the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after purchasing an additional 1,118,710 shares during the last quarter. Capital International Investors lifted its holdings in shares of Zimmer Biomet by 11.5% in the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after purchasing an additional 778,467 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Zimmer Biomet by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock valued at $468,821,000 after acquiring an additional 36,611 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.28% of the company’s stock.

Analyst Ratings Changes

ZBH has been the topic of several recent analyst reports. Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. William Blair initiated coverage on Zimmer Biomet in a research note on Friday, February 20th. They set a “market perform” rating on the stock. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Robert W. Baird set a $92.00 target price on Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Citigroup cut their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Stock Up 1.6%

Shares of Zimmer Biomet stock opened at $88.54 on Friday. The business’s fifty day moving average price is $87.56 and its two-hundred day moving average price is $90.43. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The company has a market capitalization of $17.13 billion, a P/E ratio of 23.00, a PEG ratio of 2.01 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period last year, the firm earned $1.81 EPS. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.